CompletedNCT01396291
Asenapine or Placebo to Prevent Mood Episodes in Bipolarity
About this title
Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384)
Read the official source — NCT01396291Medication studyAges 18+Multiple countries
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Anaheim and 79 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateDecember 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 561
- Sponsor
- Forest Laboratories
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Bulgaria, Croatia, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT01396291
- Official title
Show the full official title
A Double-Blind, Placebo-Controlled Trial of Asenapine in the Prevention of Recurrence of a Mood Episode After Stabilization of an Acute Manic/Mixed Episode in Subjects With Bipolar 1 Disorder (Phase 3B, Protocol P06384)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Anaheim, United States · Chino, United States · Escondido, United States
62 more locations
- National City, United States
- Oakland, United States
- Orange, United States
- Torrance, United States
- Colorado Springs, United States
- Jacksonville, United States
- Kissimmee, United States
- Leesburg, United States
- Miami, United States
- Tampa, United States
- Atlanta, United States
- Chicago, United States
- Schaumburg, United States
- Witchita, United States
- Gladstone, United States
- Albuquerque, United States
- Elmsford, United States
- Avon Lake, United States
- Cincinnati, United States
- Oklahoma City, United States
- Memphis, United States
- Houston, United States
- Irving, United States
- Plano, United States
- Wichita Falls, United States
- Pleven, Bulgaria
- Sofia, Bulgaria
- Varna, Bulgaria
- Burgas, Bulgaria
- Zagreb, Croatia
- Rijeka, Croatia
- Nashik, India
- Ahmedabad, India
- Kanpur, India
- Hyderabad, India
- Cebu, Philippines
- Iloilo City, Philippines
- Mandaluyong, Philippines
- Manila, Philippines
- Bucharest, Romania
- Targoviste, Romania
- Iași, Romania
- Targu Mureş, Romania
- Arad, Romania
- Kazan', Russia
- Moscow, Russia
- Saint Petersburg, Russia
- Smolensk, Russia
- Belgrade, Serbia
- Kragujevac, Serbia
- Novi Kneževac, Serbia
- Korucuk, Türkiye
- Ankara, Türkiye
- Diyarbakır, Türkiye
- Chernihiv, Ukraine
- Kharkiv, Ukraine
- Kyiv, Ukraine
- Luhansk, Ukraine
- Kherson, Ukraine
- Lviv, Ukraine
- Russia
- Türkiye
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Forest Laboratories, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including asenapine and placebo.
Who was this study for?
Listed age limits: from 18 years.
